The chart below shows how CLW performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CLW sees a +1.79% change in stock price 10 days leading up to the earnings, and a +1.25% change 10 days following the report. On the earnings day itself, the stock moves by -0.04%. This data can give you a slight idea of what to expect for the next quarter's release.
Positive
Strong Q3 EBITDA Performance: We had a very good third quarter overall, delivering $64 million of adjusted EBITDA. This was in the middle of our guidance range of $58 million to $68 million.
Tissue Business Sale Proceeds: We closed on the sale of our tissue business on November 1. We expect to net approximately $850 million in cash from the sale after taxes and other customer expenses.
Share Repurchase Program: Our board approved a $100 million share repurchase program. We intend to buy back shares when they trade at a sufficient discount to what we believe to be our inherent value.
EBITDA Margin and Cash Flow Targets: We are targeting adjusted EBITDA margins of 13% to 14% and a 40% to 50% free cash flow conversion ratio. This assumes revenues of approximately $1.8 billion and includes the capture of Augusta synergies, which are primarily volume driven.
EBITDA Margin and Conversion Targets: We are targeting adjusted EBITDA margins of around 8% to 10% and up to a 20% adjusted EBITDA to free cash flow conversion ratio.
Negative
EBITDA Decline Analysis: The adjusted EBITDA for the third quarter of 2024 was $64 million, which was down from $53 million last year, indicating a decline in profitability.
Hurricane Helene Financial Impact: The impact from Hurricane Helene was around $5 million, negatively affecting the company's financial results.
Market Pricing Pressures Impact Revenue: Year-over-year results were down largely due to market pricing pressures, which have impacted revenue generation.
Adjusted EBITDA Decline: The company expects to incur $25 million to $30 million less adjusted EBITDA in the fourth quarter due to the sale of the tissue business, indicating a significant revenue loss.
Negative Price Cost Impact: The anticipated negative price cost impact for next year is projected to be between $40 million to $50 million, which could further strain financial performance.
Clearwater Paper Corporation (CLW) Q3 2024 Earnings Call Transcript
CLW.N
-5.37%